orlistat

AssetSmall moleculeAlso Xenical

Reversible inhibitor of gastric and pancreatic lipases, reducing dietary fat absorption.

Stage: Approved
Modality: Small molecule
Target: Lipid and ceramide metabolism
Indications: 2
Trials: 27
Developers: 1

Indications

2

Obesity
Approvedaccessdata.fda.gov7 Oct 2026
Overweight
Approvedaccessdata.fda.gov7 Oct 2026

Targets and what it contains4
Owner and partners1
Trials27
Evidence for its targets3
Competitors12
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 6 sources